Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome - Top-Institutions - MDSpire

Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome

  • By

  • Chaitali Anand

  • Farras Abdelnour

  • Benjamin Sipes

  • Daren Ma

  • Pedro D Maia

  • Justin Torok

  • Ashish Raj

  • July 9, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Alzheimer's Disease Research Center, Washington University in St. Louis
    Alzheimer's Disease Research Center, Washington University in St. Louis

    St. Louis, MO

    Key Differentiators

    • Neurology
    • Neurogenetics
    • Neuroimaging

  • #2

    Massachusetts General Hospital, Harvard Medical School
    Massachusetts General Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Neurology
    • Neurogenetics
    • Neuroimaging

  • #3

    University of California, San Francisco (UCSF) Memory and Aging Center
    University of California, San Francisco (UCSF) Memory and Aging Center

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neurogenetics
    • Neuroimaging

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neurogenetics
    • Neuroimaging

  • #5

    The Allen Institute for Brain Science
    The Allen Institute for Brain Science

    Seattle, WA

    Key Differentiators

    • Neurogenetics
    • Neuroinformatics
    • Neurobiology

Original Source(s)

Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome

  • by Chaitali Anand, Farras Abdelnour, Benjamin Sipes, Daren Ma, Pedro D Maia, Justin Torok, Ashish Raj

  • July 9, 2025

Related Content

ARPA-H Launches New Program to Deliver Rigorous, Gold-Standard Research Faster

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

Evaluating the GRACE voice assistant for dementia care among caregivers and healthcare professionals: An interview study